Member Richard Gervase was quoted by IAM in an article about an increase in the sale of drug royalties over the past two months, including the monetization of a patent deal relating to the world's first approved CRISPR-Cas9 therapy, Casgevy.

He says, "Synthetic royalties are a flexible form of financing. For a company that does not receive royalties (but rather will be commercializing the product itself), synthetic royalty transactions are a good way to raise capital on the basis of the value of a specific asset."

Source

IAM